These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. Bousquet J; Maasch H; Martinot B; Hejjaoui A; Wahl R; Michel FB J Allergy Clin Immunol; 1988 Sep; 82(3 Pt 1):439-46. PubMed ID: 3170992 [TBL] [Abstract][Full Text] [Related]
9. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial. Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830 [TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro immunological changes induced by a short course of grass allergy immunotherapy tablets. Panizo C; Cimarra M; González-Mancebo E; Vega A; Senent C; Martín S J Investig Allergol Clin Immunol; 2010; 20(6):454-62. PubMed ID: 21243928 [TBL] [Abstract][Full Text] [Related]
12. Grass pollen sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with seasonal allergic rhinitis. Bozek A; Kolodziejczyk K; Warkocka-Szoltysek B; Jarzab J Am J Rhinol Allergy; 2014; 28(5):423-7. PubMed ID: 25198030 [TBL] [Abstract][Full Text] [Related]
13. The safety and activity of polymerized ragweed: a double-blind, placebo-controlled trial in 81 patients with ragweed rhinitis. Grammer LC; Shaughnessy MA; Bernhard MI; Finkle SM; Pyle HR; Silvestri L; Patterson R J Allergy Clin Immunol; 1987 Aug; 80(2):177-83. PubMed ID: 3301986 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. Malling HJ; Lund L; Ipsen H; Poulsen L J Investig Allergol Clin Immunol; 2006; 16(3):162-8. PubMed ID: 16784009 [TBL] [Abstract][Full Text] [Related]
15. Pre-seasonal, subcutaneous immunotherapy: a double-blinded, placebo-controlled study in elderly patients with an allergy to grass. Bozek A; Kolodziejczyk K; Krajewska-Wojtys A; Jarzab J Ann Allergy Asthma Immunol; 2016 Feb; 116(2):156-61. PubMed ID: 26815709 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of immunotherapy with accelerated dosage schedules of polymerized grass and ragweed in patients with dual inhalant sensitivity. Grammer LC; Shaughnessy MA; Shaughnessy JJ; Patterson R J Allergy Clin Immunol; 1989 Apr; 83(4):750-6. PubMed ID: 2708735 [TBL] [Abstract][Full Text] [Related]
17. Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study. Grammer LC; Shaughnessy MA; Suszko IM; Shaughnessy JJ; Patterson R J Allergy Clin Immunol; 1984 Apr; 73(4):484-9. PubMed ID: 6707391 [TBL] [Abstract][Full Text] [Related]